Vito Palombella, PhD Joins Surface Oncology As Chief Scientific Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Surface Oncology, Inc. (Surface), a leader in the development of next-generation cancer immunotherapies, announced today the appointment of Vito J. Palombella, PhD, as Chief Scientific Officer. Dr. Palombella brings twenty years of scientific leadership and experience advancing first-in-class therapeutic programs, and a successful track record of building drug discovery and development organizations.

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.